(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.
Dianthus Therapeutics's earnings in 2026 is -$126,345,000.On average, 16 Wall Street analysts forecast DNTH's earnings for 2026 to be -$163,031,759, with the lowest DNTH earnings forecast at -$183,200,637, and the highest DNTH earnings forecast at -$135,509,645. On average, 13 Wall Street analysts forecast DNTH's earnings for 2027 to be -$186,146,219, with the lowest DNTH earnings forecast at -$219,756,727, and the highest DNTH earnings forecast at -$145,864,203.
In 2028, DNTH is forecast to generate -$202,632,047 in earnings, with the lowest earnings forecast at -$265,556,887 and the highest earnings forecast at -$161,621,139.